GlassScriptPhysician profile
Joan F Bailey
NPI 1184615023
$316,443.36
in general payments reported to CMS, 2019-2025
52 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $26K · 2021: $12K · 2022: $46K · 2023: $64K · 2024: $68K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Travel and Lodging: $29K · Food and Beverage: $8,028 · Consulting Fee: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,845.00 |
| Travel and Lodging | $28,799.42 |
| Food and Beverage | $8,027.79 |
| Consulting Fee | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $290,197.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $15,585.67 | 2019-2025 | |
| Corcept Therapeutics | $3,346.15 | 2019-2025 | Korlym |
| Amgen INC. | $851.33 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $714.79 | 2019-2025 | Synthroid |
| Dexcom, INC. | $593.13 | 2020-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Insulet Corporation | $573.17 | 2019-2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $557.46 | 2019-2025 | |
| Novo Nordisk INC | $513.53 | 2019-2025 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $306.72 | 2019-2025 | Strensiq |
| Medtronic, INC. | $258.85 | 2021-2025 | Minimed 780g |
| Mannkind Corporation | $219.06 | 2019-2025 | Afrezza |
| Abbott Laboratories | $201.41 | 2019-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $158.44 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $154.56 | 2022-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $152.68 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amneal Pharmaceuticals LLC | $149.21 | 2019-2025 | Unithroid |
| Sequel Med Tech, LLC | $141.68 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $135.50 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.03 | 2019-2025 | Jardiance |
| Radius Health, INC. | $131.89 | 2019-2025 | Tymlos |
| Neurocrine Biosciences, INC. | $131.86 | 2025 | |
| Medtronic Minimed, INC. | $118.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $114.43 | 2019 | |
| Horizon Therapeutics Plc | $108.54 | 2019-2023 | Tepezza |
| Recordati_rare_diseases_inc. | $102.61 | 2024-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $70.60 | 2022-2024 | Gvoke Hypopen |
| Becton, Dickinson and Company | $62.63 | 2022 | |
| Pfizer INC. | $61.83 | 2019-2020 | |
| Echosens North America, INC. | $55.00 | 2022 | |
| Ascendis Pharma Endocrinology INC | $47.51 | 2024-2025 | Yorvipath |
| Zealand Pharma US, INC. | $44.04 | 2021 | |
| Rgh Enterprises LLC | $35.55 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.32 | 2020 | |
| Companion Medical, INC. | $33.19 | 2019-2020 | |
| Amarin Pharma, INC. | $30.55 | 2020-2021 | |
| Ibsa Pharma INC. | $30.00 | 2025 | Tirosint, Flector, Licart |
| Ipsen Biopharmaceuticals, INC | $28.96 | 2019 | |
| Embecta Corp. | $27.90 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Vivus LLC | $27.86 | 2019 | |
| Endo Pharmaceuticals INC. | $22.15 | 2019 | |
| Lifescan, INC. | $20.50 | 2019 | |
| Amryt Pharma Holdings LTD | $19.73 | 2023 | Mycapssa |
| Cequr Corporation | $19.31 | 2024 | Cequr Simplicity |
| Alvogen INC | $18.55 | 2022 | |
| Shire North American Group INC | $17.86 | 2019 | |
| Intuity Medical INC | $16.72 | 2022 | |
| Grt US Holding, INC. | $15.16 | 2021 | |
| Esperion Therapeutics, INC. | $15.04 | 2022 | |
| Acella Pharmaceuticals, LLC | $14.12 | 2025 | NP Thyroid 60 |
| Vistapharm, INC. | $12.57 | 2021 | |
| Valeritas, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.